STXS

Stereotaxis, Inc. 10-Q Summary: Quarter Ended March 31, 2006

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Stereotaxis, Inc., a medical device company designing and marketing the Stereotaxis System for interventional cardiology. The report covers the three-month period ended March 31, 2006. The company is an accelerated filer incorporated in Delaware.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 66% to $1.73 million, driven primarily by a sharp drop in systems revenue ($0.98 million vs. $4.63 million) due to fewer system deliveries. Conversely, revenue from disposables, service, and accessories increased 63% to $0.75 million.
• Margin Compression: Gross margin percentage fell from 52% to 29%. While unit costs for systems decreased by approximately 20%, the margin was adversely affected by unabsorbed overhead costs resulting from reduced production and installation schedules.
• Expense Increases: Operating expenses rose 48% to $15.02 million.
  • Research and Development (R&D) increased 61% to $6.13 million due to expanded projects and integration efforts.
  • Sales and Marketing increased 42% to $5.13 million due to hiring and expanded programs.
  • General and Administrative expenses increased 39% to $3.77 million, partly due to the adoption of SFAS 123(R) for stock-based compensation.
• Liquidity Surge: Cash and cash equivalents increased by $39.24 million, primarily due to a public offering of 5.5 million shares in February 2006, which generated approximately $61.9 million in net proceeds.

Guidance, Outlook, and Risks

• Outlook: Management expects negative cash flow from operations to continue through most of 2007. R&D and SG&A expenses are expected to increase to support product commercialization and public company compliance.
• Capital Resources: The company believes existing cash, cash equivalents, and investments are sufficient to fund operations for the next 12 months. However, additional financing may be required, which could be dilutive.
• Key Risks:
  • Market Adoption: The Stereotaxis System is expensive and novel; hospital adoption may be slow.
  • Regulatory: Future revenue depends on FDA clearances for new disposable interventional devices, which are currently limited.
  • Collaborations: Significant revenue relies on partnerships with Siemens, Philips, and Biosense Webster; failure of these collaborations could materially harm the business.
  • Competition: Established manual interventional methods and emerging non-magnetic navigation devices pose competitive threats.
• Unusual Items: The adoption of SFAS 123(R) effective January 1, 2006, resulted in approximately $0.9 million of share-based compensation expense, increasing the net loss by approximately $0.4 million compared to prior accounting methods.

Investor Verification Checklist

• Verify the status and timeline of FDA clearances for new disposable interventional devices, as these are critical for future revenue growth.
• Monitor the progress and stability of strategic collaborations with Siemens, Philips, and Biosense Webster.
• Assess the company's ability to absorb overhead costs as system delivery volumes fluctuate.
• Review the burn rate of cash relative to the $61.9 million raised in the recent offering to confirm the 12-month liquidity runway.
• Track the conversion rate of purchase orders to recognized revenue, noting the long sales and installation cycles (often 9+ months).